România -
română -
ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)
enhancin 500 mg/125 mg
terapia s.a. - romania - kalii + acid clavulanicum - compr. film. - 500mg/125mg - peniciline cu spectru larg peniciline in combinatii incl. inhibitori de betalactamaza
România -
română -
ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)
enhancin 875 mg/125 mg
terapia sa - romania - kalii + acid clavulanicum - compr. film. - 875mg/125mg - antibiotice beta-lactamice, peniciline peniciline in combinatii incl. inhibitori de betalactamaza
România -
română -
ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)
enhancin 500 mg/125 mg
terapia s.a. - romania - kalii + acid clavulanicum - compr. film. - 500mg/125mg - antibiotice beta-lactamice, peniciline peniciline in combinatii incl. inhibitori de betalactamaza
România -
română -
ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)
fingolimod zentiva 0,5 mg
zentiva s.a. - romania - fingolimodum - caps. - 0,5mg - imunosupresoare imunosupresoare selective
România -
română -
ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)
fingolimod tiefenbacher 0,5 mg
delorbis pharmaceuticals ltd. - cipru - fingolimodum - caps. - 0,5mg - imunosupresoare imunosupresoare selective
Uniunea Europeană -
română -
EMA (European Medicines Agency)
tysabri
biogen netherlands b.v. - natalizumab - scleroză multiplă - imunosupresoare selective - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 și 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
Uniunea Europeană -
română -
EMA (European Medicines Agency)
lumeblue (previously known as methylthioninium chloride cosmo)
alfasigma s.p.a. - metiltioniniu - colorectal neoplasms; colonoscopy - other diagnostic agents - lumeblue is indicated as a diagnostic agent enhancing visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy.
Uniunea Europeană -
română -
EMA (European Medicines Agency)
fingolimod mylan
mylan ireland limited - fingolimod clorhidrat de - scleroză multiplă, scleroză multiplă recurent-remisivă - imunosupresoare - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 și 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
Uniunea Europeană -
română -
EMA (European Medicines Agency)
tyruko
sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresoare - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 și 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.